Obizur
susoctocog alfa · Baxalta Innovations GmbH
EXCEPTIONAL CIRCUMSTANCES AUTHORISED IN THE EUWhat Obizur is used for
Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Obizur
- Active substance
- susoctocog alfa
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02
- Marketing authorisation holder
- Baxalta Innovations GmbH
- Authorised in the EU since
- 2015
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Obizur used for?
Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults.
What is the active substance in Obizur?
Obizur contains susoctocog alfa.
Who makes Obizur?
The EU marketing authorisation holder is Baxalta Innovations GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU